Search

Displaying results 5321 - 5330 of 10000 in total
  1. Drug

    NV1020

    go.drugbank.com/drugs/DB04969
    Investigational

    NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

  2. Drug

    Moexiprilat

    go.drugbank.com/drugs/DB14210
    Experimental

    The active metabolite of the prodrug Moexipril.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    TJ003234

    go.drugbank.com/drugs/DB16470
    Investigational

  4. Drug

    Cyclopenthiazide

    go.drugbank.com/drugs/DB13532
    Approved

    In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [A27180]. … It is a positive allosteric modulator at AMPA-A receptors [T28].

  5. Drug

    Hydrogen fluoride

    go.drugbank.com/drugs/DB11072
    ApprovedInvestigational

    It is used as a chemical reagent in several industrial processes such as oil refinery. It is also used as etchant, cleaning agent, and a reagent to dissolve oxides and silicates. … Hydrogen fluoride (Hydrofluoric acid) is a weak acid that is a precursor to almost all fluorine compounds, including pharmaceuticals such as [DB00472] (Prozac).

  6. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

  7. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

  8. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  9. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.

  10. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    in mice) studies. … [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.